Wai Meng David Tai

4PUBLICATIONS

60CO-AUTHORS

Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (4)

Sort by Publication Date:

|Jun 25, 2026

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

|Jul 22, 2021

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.

Robin Kate Kelley, Bruno Sangro, William Harris

|May 03, 2021

Resected pancreatic adenocarcinoma: An Asian institution's experience.

Kennedy Yao Yi Ng, Edwin Wei Xiang Chow, Bochao Jiang

|Sep 03, 2020

Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.

Kennedy Yao Yi Ng, Lawrence Wen Jun Wong, Andrea Jing Shi Ang

Pageof 1

Frequent Collaborators

Joycelyn Jie Xin Lee

Kennedy Yao Yi Ng

Edwin Wei Xiang Chow

Bochao Jiang

Cindy Lim

Brian Kim Poh Goh

Jin Yao Teo

Damien Meng Yew Tan

Peng Chung Cheow

London Lucien Peng Jin Ooi

Frequent Collaborators

Joycelyn Jie Xin Lee

Kennedy Yao Yi Ng

Edwin Wei Xiang Chow

Bochao Jiang